Anthracycline-induced cardiomyopathy in the long-term period after chemotherapy: clinical case

Background. As is known, the treatment of oncological process leads either to occurrence cardiovascular pathology, or an increase in risk death from diseases. Currently, concept ˝cardiovascular toxicity˝ has been introduced, which associated with cancer (CTR-CVT). Systemic drug anthracycline-containing anticancer therapy can cause a number complications, such as myocardial systolic dysfunction, coronary heart disease, cardiac arrhythmias, arterial hypertension. Particular attention paid anthracycline drugs, because they are still included combinations many adjuvant regimens and first-line both most common cancers rarer ones.
 Clinical Case Description. The article presents clinical case patient who received polychemotherapy for breast 2017 AC 4 D regimen, chronic anthracycline-induced cardiomyopathy manifested years after completion antitumor therapy. development possible even patients initially low risk.
 Conclusion. highlights importance monitoring end therapy, particular, shown periodically perform echocardiographic study order detect delayed asymptomatic dysfunction.